Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2019-06-04 Declaration of Voting R…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations, and presents a table showing the total number of shares and voting rights as of May 31, 2019. This content directly relates to changes in the company's capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a formal publication, it is not a general regulatory filing (RNS) because it fits a more specific category related to capital structure.
2019-06-04 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document explicitly announces the "Voting results of Theradiag's Annual Ordinary and Extraordinary General Meeting" held on May 16th, 2019. It details the adoption or rejection of various resolutions, including the ratification of management appointments and financial approvals. This content directly relates to the outcomes of a shareholder meeting. The most specific category for official results from a general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it relates to an AGM, AGM-R is for presentations/materials, whereas DVA is for the results themselves, which this document provides in detail.
2019-06-03 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document explicitly details the "Résultat des votes de l'Assemblée Générale Ordinaire Annuelle et Extraordinaire" (Results of the votes of the Annual and Extraordinary General Meeting). It includes specific voting tables for resolutions passed during the Ordinary General Meeting (approbation des comptes, ratification de cooptation) and the Extraordinary General Meeting (augmentation de capital, etc.). This content directly corresponds to the official results of a shareholder vote following a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-06-03 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated May 14, 2019, announcing a new contract and strategic acceleration in the US market, involving rebranding and operational changes. It discusses business strategy, market penetration, and future plans. Crucially, it concludes with a section titled "Next financial press release" which schedules the announcement of "Half-yearly sales 2019". This structure—a strategic business update combined with a forward-looking announcement about the next scheduled financial report—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not the actual financial results but an announcement about business strategy and a future reporting date, and it doesn't fit the specific definitions of M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it is best classified as a general corporate announcement. Given the options, it most closely resembles an Earnings Release (ER) if it were summarizing results, but since it is purely strategic and forward-looking, and doesn't fit the other specific categories, it falls under the general regulatory announcement category, RNS, as a fallback for significant, non-standard corporate news that isn't a formal report itself. However, because it is a press release announcing strategic business developments rather than a mandatory regulatory filing, and it is not a transcript (CT) or a formal report (10-K, IR), RNS is the most appropriate catch-all for significant, non-standard corporate news releases.
2019-05-14 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated May 14, 2019, announcing a strategic business development (a new contract with HalioDx to accelerate US market presence) and includes a forward-looking statement about the next financial release (H1 2019 revenue on July 25, 2019). It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial announcement like an Earnings Release (ER) which usually contains summarized figures. It is a general corporate announcement regarding strategy and operations. Since it doesn't fit perfectly into the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), and it is a formal announcement, the most appropriate general category for non-standard corporate news that isn't a specific financial report or proxy material is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere.
2019-05-14 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations regarding the total number of shares and voting rights as of a specific date (April 30, 2019). This type of mandatory disclosure regarding the capital structure and voting power falls under announcements related to share capital changes or regulatory updates. Since the document details the total number of shares and voting rights, it directly relates to the company's capital structure. The closest specific category is 'Share Issue/Capital Change' (SHA), as it reports the current state of the capital base. It is not a general regulatory filing (RNS) because it is highly specific to capital structure reporting, nor is it a transaction in own shares (POS) which implies a buyback or issuance event, but rather a periodic statement of the total outstanding shares.
2019-05-02 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.